Keryx Biopharmaceuticals News (NASDAQ:KERX)
| Latest Keryx Biopharmaceuticals News Headlines | | Date | Time | Source | | | 06/24/2008 | 8:29AM | PRNUS | Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
Presentation Scheduled for Thursday, June 26th at 2:30pm ET
NEW YORK, June 24 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, is scheduled to present at the Jefferies & Co. Healthcare Conference being held... More...>> |
| 06/03/2008 | 9:15AM | PRNUS | Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstr
Dr. Irene Ghobrial of the Dana-Farber Cancer Institute presents phase 2 results demonstrating the single agent clinical activity of perifosine in patients with relapsed / refractory Waldenstroms Macroglobulinemia
NEW YORK, June 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced... More...>> |
| 06/02/2008 | 7:59AM | PRNUS | Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at
Phase 2 Results of Perifosine in the Treatment of Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia to be presented Tomorrow, Tuesday, June 3rd at 12:00pm in Room E450a
NEW YORK, June 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that abstracts related to KRX-0401... More...>> |
| 05/13/2008 | 8:30AM | PRNUS | Keryx Biopharmaceuticals to Present at the Bank of America 2008 Health Care Conference
Presentation Scheduled for Thursday, May 15th at 11:10am PT
NEW YORK, May 13 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, is scheduled to present at the Bank of America 2008 Health Care Conference in... More...>> |
| 05/09/2008 | 5:30PM | PRNUS | Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
Keryx to Host Investor Conference Call on Monday, May 12, 2008 at 8:30am EDT
NEW YORK, May 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the... More...>> |
| 05/08/2008 | 5:27PM | PRNUS | Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. E
NEW YORK, May 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) will hold a conference call on Monday, May 12, 2008 at 8:30 a.m. EDT to discuss the first quarter 2008 financial results. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce... More...>> |
| 05/05/2008 | 8:29AM | PRNUS | Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
Presentation Scheduled for Wednesday, May 7th at 9:30am EDT
NEW YORK, May 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, is scheduled to present at the Deutsche Bank 33rd Annual Health Care Conference... More...>> |
| 04/25/2008 | 5:00PM | PRNUS | Keryx Biopharmaceuticals Receives Nasdaq Notification
NEW YORK, April 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced today that it has received notice from The NASDAQ Stock Market ("Nasdaq") stating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued inclusion on the Nasdaq Global Market... More...>> |
| 04/07/2008 | 9:08AM | PRNUS | Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
Plan to Include Refocusing of Operations and Workforce Reduction
NEW YORK, April 7, 2008 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals (NASDAQ:KERX) today announced that it is implementing a strategic restructuring plan to reduce its cash burn rate and re-focus its development efforts. The plan, which was prompted... More...>> |
| 04/04/2008 | 8:01PM | PRNUS | Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
Plan includes refocusing of operations and workforce reduction
NEW YORK, April 4, 2008 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals (NASDAQ:KERX) today announced that it is implementing a strategic restructuring plan to reduce its cash burn rate and re-focus its development efforts. The plan, which was prompted... More...>> |
| 03/27/2008 | 4:31PM | PRNUS | Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
NEW YORK, March 27 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced today that following a Drug Safety and Monitoring Committee (DSMC) review of the SUN-MACRO Phase 4 trial of Sulonex(TM) (sulodexide oral gelcap), the Company has decided to terminate the study and cease further development... More...>> |
| 03/13/2008 | 8:29AM | PRNUS | Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
Presentation Scheduled for Monday, March 17th at 11:30am ET
NEW YORK, March 13 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that I. Craig Henderson, MD, the Company's President, and Eric Grossman, MD, the Company's Vice President, Medical Affairs, are scheduled to present at... More...>> |
| 03/10/2008 | 7:29AM | PRNUS | Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Company to host conference call Today, Monday, March 10, 2008 at 8:30am
NEW YORK, March 10 /PRNewswire-FirstCall/ -- On Friday, March 7, 2008, Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), announced top-line results from its SUN-MICRO Phase 3 clinical trial of Sulonex (sulodexide) for the treatment of diabetic nephropathy... More...>> |
| 03/07/2008 | 8:00PM | PRNUS | Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Company to host a conference call Monday, March 10, 2008 at 8:30am
NEW YORK, March 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced top-line results from its SUN-MICRO Phase 3 clinical trial of Sulonex (sulodexide) for the treatment of diabetic nephropathy. The Company announced... More...>> |
| 02/22/2008 | 5:06PM | PRNUS | Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
Keryx to Host Investor Conference Call on Monday, February 25, 2008 at 8:30am EST
NEW YORK, Feb. 22 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for... More...>> |
| 02/21/2008 | 4:35PM | PRNUS | Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February
NEW YORK, Feb. 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) will hold a conference call on Monday, February 25, 2008 at 8:30 a.m. EST to discuss the fourth quarter and year-end 2007 financial results and business outlook for 2008. Michael S. Weiss, Chairman and Chief Executive Officer of... More...>> |
| 02/15/2008 | 8:00AM | PRNUS | Keryx Biopharmaceuticals Announces Additions to Management Team
Key Hires in Quality Operations and Medical Affairs
NEW YORK, Feb. 15 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that Lou DeBergalis has joined the Company as Vice President, Quality Operations. Keryx also announced that Eric Grossman, MD, will join the Company later this... More...>> |
| 02/05/2008 | 8:30AM | PRNUS | Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
NEW YORK, Feb. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will be presenting at the following upcoming Investor Conferences:
Thursday, February 7th, 2008 - 10:20 AM ET:
Merrill Lynch 19th Global... More...>> |
| 01/03/2008 | 8:29AM | PRNUS | Keryx Biopharmaceuticals to Present at JPMorgan Healthcare Conference
NEW YORK, Jan. 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, is scheduled to present at the upcoming JPMorgan 26th Annual Healthcare Conference, taking place in San Francisco. Mr. Weiss' presentation... More...>> |
| 12/10/2007 | 8:21AM | PRNUS | Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory
Dr. Paul Richardson presents Phase 1 results demonstrating clinical activity of perifosine in combination with bortezomib in patients previously treated with bortezomib, and provides an update on an ongoing Phase 2 study of perifosine in combination with dexamethasone
NEW YORK, Dec. 10 /PRNewswire-FirstCall/ -- Keryx... More...>> |
|
|
|